Back to top
more

Aduro Biotech, Inc. (ADRO)

(Delayed Data from NSDQ)

$4.26 USD

4.26
328,546

+0.11 (2.65%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's in Store for Sangamo (SGMO) This Earnings Season?

by Zacks Equity Research

On Sangamo (SGMO) Q4 conference call, investors will look into genome editing development and gene regulation technology platform, used for inventing genomic therapies to address unmet medical needs.

The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

by Zacks Equity Research

The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna

Will Aduro Biotech Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Aduro Biotech.

Swarup Gupta headshot

5 Tiny Biotech Stocks With Superb Growth Potential

by Swarup Gupta

A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100

by Zacks Equity Research

Aduro (ADRO) doses the first patient in a phase I study on ADU-S100 in combination with Yervoy for the treatment of relapsed and refractory melanoma. Shares rise.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.

Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely?

by Zacks Equity Research

Merrimack (MACK) regains its status as a development-stage biopharma company after the sale of its sole marketed product Onivyde in 2017.

AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates

by Zacks Equity Research

AMAG encourages with narrower-than-expected loss in Q4 while revenues fall shy of estimates.

Vanda (VNDA) Q4 Earnings: What's in Store for the Stock

by Zacks Equity Research

On Vanda's (VNDA) fourth-quarter 2018 conference call, investor focus will be on the sales figure of its two marketed drugs, Hetlioz and Fanapt.

Will Aduro Biotech Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Aduro Biotech.

Top Ranked Momentum Stocks to Buy for February 6th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 6th:

Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study

by Zacks Equity Research

Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.

Vertex Terminates COO Ian Smith on Code of Conduct Violation

by Zacks Equity Research

Vertex (VRTX) announces termination of its chief operating officer, Ian Smith, owing to violation of the company's code of conduct and values.

Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition

by Zacks Equity Research

Amicus (FOLD) is well placed after the United States approved its only marketed drug, Galafold, and the company added 14 new gene therapy programs to its pipeline for rare metabolic diseases.

Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids

by Zacks Equity Research

Vertex (VRTX) gains an EU approval for Orkambi to treat 2-5-year-old children suffering cystic fibrosis (CF).

Aduro Biotech (ADRO) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Aduro Biotech (ADRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Top Ranked Momentum Stocks to Buy for January 8th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 8th:

Aduro BioTech (ADRO) Looks Good: Stock Adds 7.7% in Session

by Zacks Equity Research

Aduro BioTech (ADRO) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte

Aduro Stock Surges on STING Activator Deal With Eli Lilly

by Zacks Equity Research

Aduro (ADRO) inks a collaboration/license deal with Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS-STING inhibitor platform.

Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY

by Zacks Equity Research

A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.

Aduro Biotech Enters Oversold Territory

by Zacks Equity Research

Aduro Biotech has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Why Is Aduro Biotech (ADRO) Down 40.1% Since Last Earnings Report?

by Zacks Equity Research

Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag

by Zacks Equity Research

Aduro's loss (ADRO) betters estimates in Q3. However, lower license and collaboration fees induce a dip in year-over-year revenues.

Aduro Biotech (ADRO) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aduro Biotech (ADRO) delivered earnings and revenue surprises of 6.45% and -33.21%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?